Stockscreener 앱 받기
234.80
0.28%
-1.17
전일 마감가:
$235.97
열려 있는:
$236.79
하루 거래량:
261.14K
Relative Volume:
0.37
시가총액:
$12.10B
수익:
$708.24M
순이익/손실:
$-188.30M
주가수익비율:
-62.79
EPS:
-3.7392
순현금흐름:
$-70.99M
1주 성능:
+3.81%
1개월 성능:
+26.54%
6개월 성능:
+55.85%
1년 성능:
+123.95%
1일 변동 폭
$233.63
$238.56
1주일 범위
$224.00
$238.56
52주 변동 폭
$96.09
$238.56
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
235.11 | 12.14B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
436.35 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.49 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.00 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.23 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.84 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 개시 | B. Riley Securities | Buy |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
New AUVELITY depression data, sleep apnea study head to ASCP 2026 - Stock Titan
Axsome Therapeutics, Inc. $AXSM Shares Acquired by Legato Capital Management LLC - MarketBeat
Axsome Therapeutics stock hits all-time high at 236.84 USD By Investing.com - Investing.com Nigeria
Axsome Therapeutics Climbs Higher On Nasdaq Momentum - Kalkine Media
Technical Reactions to AXSM Trends in Macro Strategies - Stock Traders Daily
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 1-Year HighShould You Buy? - MarketBeat
Axsome Therapeutics stock hits all-time high at 236.84 USD - Investing.com
AXSM Stock Price, Quote & Chart | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome wins FDA label expansion for Auvelity in Alzheimer’s agitation - MSN
AXSM Technical Analysis | Trend, Signals & Chart Patterns | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
AXSM: June launch of new Alzheimer's agitation drug, expanded sales force, and robust pipeline progress - TradingView
Axsome Therapeutics (AXSM) price target increased by 18.66% to 272.70 - MSN
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: High Growth Potential with 18.69% Upside - DirectorsTalk Interviews
Why is Axsome (AXSM) down 6.6% since last earnings report? - MSN
Axsome projects Auvelity peak sales of at least $8B following Alzheimer's agitation approval and June launch - MSN
AXSM stock clocks best day in about 4 months on FDA greenlight for Alzheimer’s drug - MSN
Axsome Therapeutics bets on AUVELITY expansion with June Alzheimer's agitation launch - MSN
Axsome stock climbs on schizophrenia drug deal with Takeda - MSN
Axsome's Auvelity: A New Treatment For Agitation In Alzheimer's Disease (AXSM) - Seeking Alpha
AXSM Stock Chart | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome Therapeutics stock hits all-time high at 234.57 USD - Investing.com India
Axsome Therapeutics stock hits all-time high at 234.57 USD By Investing.com - Investing.com Nigeria
AXSM stock is rising today after Wall Street’s positive stance despite mixed Q1 – what's behind the optimism? - MSN
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch - sharewise.com
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $258 - Moomoo
Strong drug sales lift Axsome revenue, but profit miss drags stock - MSN
Trading the Move, Not the Narrative: (AXSM) Edition - Stock Traders Daily
White & Case advises Takeda on divestment to Axsome Therapeutics - White & Case LLP
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Understanding the 24% Potential Upside in CNS Treatments - DirectorsTalk Interviews
Axsome Q1 2026 slides: 57% revenue surge, $18B peak sales target - Investing.com Nigeria
Axsome Q1 2026 slides: 57% revenue surge, $18B peak sales target By Investing.com - Investing.com South Africa
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results By Investing.com - Investing.com Australia
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results - Investing.com
The week in pharma: action, reaction and insight – week to May 8, 2026 - The Pharma Letter
Axsome Therapeutics, Inc. $AXSM Holdings Decreased by State of New Jersey Common Pension Fund D - MarketBeat
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310 - Moomoo
3 Stocks Poised to Disrupt the Healthcare Market by 2030 - The Motley Fool
Principal Financial Group Inc. Lowers Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Axsome Therapeutics Inc 주식 (AXSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Option Exercise |
12.95 |
233 |
3,017 |
233 |
| Jacobson Mark L. | Chief Operating Officer |
May 04 '26 |
Sale |
227.94 |
4,517 |
1,029,605 |
0 |
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Sale |
228.18 |
233 |
53,166 |
0 |
2.25%
0.46%
자본화:
|
볼륨(24시간):